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Despite half a century of dedicated studies, medication adherence remains far from perfect, with many patients not taking their
medications as prescribed. The magnitude of this problem is rising, jeopardizing the effectiveness of evidence-based therapies.
An important reason for this is the unprecedented demographic change at the beginning of 21st century. Ageing leads to
multimorbidity and complex therapeutic regimens that create fertile ground for non-adherence. As this scenario is a global
problem, it needs a worldwide answer. Might we find this answer thanks to new opportunities created by the digitization of
healthcare?
Day by day health-related information is collected in electronic health records, pharmacy dispensing databases, health insurance
systems and national health system records. These Big Data repositories offer an unprecedented opportunity to study adherence
both retrospectively and prospectively, at the population level, as well as its related factors. If only we had widely accepted
standard measures of adherence, we could use this data to inform health research, clinical practice and public health. These
standards could also help us to better understand the relationship between adherence and clinical outcomes, and allow for fair
benchmarking of effectiveness and cost-effectiveness of adherence-targeting interventions. 
Unfortunately, despite this obvious need, we are still far from having sound standards of formatting, and analyzing Big Data in
order to assess, uniformly present and compare patterns of medication adherence across studies. The aim of this paper is to call
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The need for patient adherence standard measures for Big Data. 
Abstract
Despite half a century of dedicated studies, medication adherence remains far from perfect,
with  many  patients  not  taking  their  medications  as  prescribed.  The  magnitude  of  this
problem is rising, jeopardizing the effectiveness of evidence-based therapies. An important
reason for this is the unprecedented demographic change at the beginning of 21st century.
Ageing leads to multimorbidity and complex therapeutic regimens that create fertile ground
for non-adherence. As this scenario is a global problem, it needs a worldwide answer. Might
this  answer  be  provided,  given  the  new  opportunities  created  by  the  digitization  of
healthcare?
Day by day health-related information is collected in electronic health records, pharmacy
dispensing  databases,  health  insurance  systems  and  national  health  system  records.
These Big Data repositories offer a unique chance to study adherence both retrospectively
and prospectively, at population level, as well as its related factors. In order to make the full
use of this opportunity, there is a need to develop standardised measures of adherence,
which can be applied globally to Big Data and will inform scientific research, clinical practice
and public health. These standardized measures may also enable a better understanding of
the relationship between adherence and clinical outcomes, and allow for fair benchmarking
of effectiveness and cost-effectiveness of adherence-targeting interventions. 
Unfortunately, despite this obvious need, such standards are still lacking. Therefore, the aim
of  this  paper  is  to  call  for  producing  a  consensus  on  global  standards  for  measuring
adherence with Big Data. More specifically, sound standards of formatting, and analysing
Big  Data  are  needed  in  order  to  assess,  uniformly  present  and  compare  patterns  of
medication  adherence  across  studies.  Wide  use  of  these  standards  may  improve
adherence, and make healthcare systems more effective and sustainable.
List of abbreviations: 
ABC  –  Ascertaining  Barriers  for  Compliance  project,  AI  -  Artificial  Intelligence,  EIP  on  AHA -
European Innovative Partnership on Active and Healthy Ageing, EHR - electronic health record,
EMA -  European Medicines  Agency,  EMERGE – ESPACOMP Medication  Adherence Reporting
Guideline,  ESPACOMP  -  International  Society  for  Medication  Adherence,  HMA  -  Heads  of
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Medicines Agencies,  ISO -  International  Organization for  Standardization,  ISPOR -  International
Society  for  Pharmacoeconomics  and Outcomes  Research,  IT -  Information Technology,  MPR -
medication possession ratio, PDC - proportion of days covered, WHO - World Health Organization
Introduction 
Despite half a century of dedicated studies, medication adherence remains far from perfect.
In fact, non-adherence to medication - i.e. the scenario in which the patients are not taking
their  medications as  prescribed -  is  still  very  prevalent.  According  to  the  World  Health
Organization (WHO), 50% of patients are estimated to deviate from their chronic treatments
[1]. Jeopardizing the effectiveness of evidence-based therapies, it has been shown to lead
to poor health outcomes, increased use of health services and increased costs (both direct,
as well as indirect e.g. due to absenteeism, lost productivity etc.) [2].  In a recent meta-
analysis, medication non-adherence has been found to be significantly associated with all-
cause hospitalization and mortality in older people [3]. Thus, non-adherence is an important
determinant of individual health. On population level, it also seriously affects public health,
and the  economy.  Due to  this  all,  non-adherence has been recognized by  WHO as a
“problem of striking magnitude” [1].
Unfortunately, the seriousness of this problem is ever increasing. An important reason for
this is the unprecedented demographic change that is taking place at the beginning of 21 st
century. It affects the whole world, and is particularly pronounced in Europe. According to
Eurostat, currently, persons aged 65 years and older comprise 20% of EU-28 population
and this proportion is expected to rise up to 31% by 2100. Even more striking are the
statistics for very old citizens – those aged 80+ are expected to rise within the same time
period from current 6% of EU-28 population to 15%. [4] 
Longer  lifespan  results  in  an  increase  in  the  prevalence  of  non-communicable  chronic
conditions and multimorbidity (usually defined as the coexistence of two or more chronic
conditions in an individual). This, in turn, leads to the frequent use of complex therapeutic
regimens and creates fertile ground for non-adherence. [5]. 
In  order  to  prevent  non-adherence,  one  needs  to  know  the  major  drivers  of  this
phenomenon. The WHO developed a model of the determinants affecting adherence and
grouped them into five main sets of factors: health system related factors, therapy related
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factors,  condition related factors,  patient  related factors,  and socioeconomic factors [1].
Based on this model  of  adherence, multiple non-adherence-targeting interventions have
been designed and tested but unfortunately only few have been successful. As stated in a
recent Cochrane systematic review, “current methods of improving medication adherence
for  chronic  health  problems are mostly  complex and not  very effective,  so that  the full
benefits of treatment cannot be realized”. [6].
Indeed, medication taking is a complex behaviour, and diverse determinants play different
roles at the individual level. In a consequence, it seems to be unrealistic to expect that one
uniform intervention will solve the problem of non-adherence in each and every case. On
the other hand, there is a rising body of evidence that non-adherence could be effectively
managed through the use of various innovative digital solutions [7]. Successful examples
include  web-based  education  and  monitoring  programs  [8],  clinical  decision  support
systems using data from Electronic Health Records (EHRs) to produce alerts [9], mobile
technologies  (mHealth)  and  dedicated  apps  providing  various  combinations  of  patient
monitoring, education, and facilitation of adherence [10,11], etc. Thanks to digitization, for
the first time in the history, non-adherence may also become precisely measurable on a
mass  scale,  due  to  the  availability  of  large  health  care  databases.  This  is  particularly
important for older populations, which is a group usually understudied in clinical trials for
various reasons (e.g. multimorbidity and related polymedication). 
However, these promising opportunities are not fully utilized yet due to the lack of basic
widely  accepted  standards  for  measuring  and  managing  adherence  in  Big  Data.  The
discussion that started in 2019 at the forums of professional bodies active at the area of
patient adherence research, i.e. Action Group A1 ‘Adherence to prescription and medical
plans’ of the European Innovative Partnership on Active and Healthy Ageing (EIP on AHA)
and International Society for Medication Adherence ESPACOMP, to which the authors of
this publication belong, led to the conclusion that this scenario needs to be changed. This
idea corresponds very well with recent recommendations of the HMA-EMA joint Big Data
Task Force, which called for the development of skills and the creation of capabilities to
analyse  Big  Data  [12].  Therefore,  the  aim  of  this  publication  is  to  establish  a  call  for
producing a consensus on global standards for measuring adherence with Big Data. More
specifically, sound standards of formatting, and analysing Big Data are needed in order to
assess, uniformly present and compare patterns of medication adherence across studies,
and thus, help scientific research, clinical practice, and public health. 
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Opportunities created for adherence due to digitization of the healthcare sector
Digitization is a new opportunity that has, in recent times, become more frequently adopted
in  the  healthcare  sector.  Interestingly  to  date,  digital  solutions  have  been  widely  used
outside  healthcare,  but  only  recently  have  they  have  become employed  in  the  field  of
medicine and offer great promise towards improved and more efficient care. In order to
speed up this process, in 2018 the European Commission developed a plan for the digital
transformation of health and care in the Digital Single Market. The plan is based on three
pillars;  (i)  secure  data  access  and sharing;  (ii)  connecting  and sharing  health  data  for
research,  faster  diagnosis  and  improved  individualized  healthcare  services  and  health
outcomes and; (iii) strengthening citizen empowerment and individual care through digital
services  [13].  This  plan  is  a  part  of  the  overarching  European  Strategy  for  Data  [14].
Digitization of the healthcare sector creates an opportunity for using Big Data analytics tools
and methods to assess non-adherence, improve clinical practice/healthcare services and
promote the use of tailored interventions. Routinely collected information on prescribing and
dispensing  which  are  available  in  electronic  health  records,  pharmacy  dispensing
databases, health insurance claims systems, and national health systems records, enables
a more thorough exploration of the relationship between adherence and health outcomes.
The rising use of mHealth by patients for self-monitoring and disease management is also
another potential data source for analysing. Thus, Big Data may represent a powerful and
relatively low-cost resource for investigating important public health concerns in real-life
scenarios:  prevalence  of  non-adherence,  its  drivers  and  the  consequences  of  non-
adherence.  Big  Data  can  also  be  used  to  provide  information  for  designing  new
interventions, targeting both prevention and management of non-adherence. Moreover, Big
Data allows research on an incomparable scale, covering large populations (e.g. primary
non-adherence - a measure of unfilled prescriptions - was recently assessed in a cohort of
1.6 million Catalonian primary care patients [15], and in a national population based study
in Poland [16]).  Unlike medical  trials,  Big  Data also provides the opportunity  to  assess
adherence  longitudinally  (e.g.  an  Estonian  study  analysed  a  national  database  over  a
period of 15 years [17]).  All  this is possible without typical limitations in terms of costs,
intrusiveness or bias, which are characteristic of studies employing other sorts of data for
adherence  measurement  and  monitoring.  However,  at  present  uniform  and  accepted
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standards of adherence measurement for Big Data are still lacking. Moreover, currently Big
Data collections are not uniformly formatted nor structured for adherence measurement,
which  means  that  non-trivial  operations  are  needed  to  allow  for  this  kind  of  analysis.
Therefore,  to  build  a  solid  evidence  base  for  adherence  management  across  clinical
settings, it is necessary to standardize adherence estimation and facilitate the appropriate
use of these standards [18]. 
Adherence research is not the only area of research to face problems with standardization,
when it comes to digital health. For example, there are no global standards for EHR still.
[19] Various historical, cultural, economic and political reasons could be citied as causative
factors that despite activities of several interoperability initiatives, both public and private,
this  is  still  the  case  [20].  Several  Standardization  Development  Organizations  have
developed very mature and widely implemented standards such as the CDA [21] and FHIR
[22]  by  HL7,  and  CEN-ISO  13606  [23],  but  they  are  limited  in  their  interoperability.
Interestingly, ISO 10781:2015 provides a reference list of functions that may be present in
an Electronic Health Record System, of which one tackles adherence assessment: Care
Patient Support CPS 3.1 Function on “Support for Standard Assessments”. [24]
A systemic review of the challenges toward the use of Big Data in healthcare identified
issues  of  data  structure,  security,  data  standardization,  storage  and  transfers,  and
managerial skills such as data governance to be those most often provided in the current
literature  [25].  Practical  challenges  include  data  pre-processing  and  curation,  model
training, refinement of the systems, ethical and legal issues, data privacy and security, end-
users understanding acceptance, and much more [26, 27].
Certainly, to overcome all these challenges is not easy. However, it is quite easy to illustrate
why this scenario urgently needs to be changed.
Need for standard Big Data-related adherence metrics for research
The  introduction  of  the  ABC  taxonomy  and  new  adherence  terminology  (named  after
dedicated European research project ‘Ascertaining Barriers for Adherence’) made the first
big step forward in terms of standardization, by defining three essential  components of
adherence.  These  components  are:  (i)  initiation  (taking  the  first  dose  of  prescribed
medication); (ii) implementation (taking medication as prescribed); and (ii) discontinuation
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(stopping  treatment)  [28].  Following  this,  the  recently  introduced  EMERGE  guideline
(ESPACOMP Medication  Adherence  Reporting  Guideline developed  under  umbrella  of
International Society for medication adherence ESPACOMP) provides guidance, along with
a checklist for reporting results of studies on medication adherence [29]. Other interesting
activities in this area include the work initiated with the support of the Government of Spain
and  the  European  project  StandICT.eu  to  generate  an  extension  of  the  Snomed  CT
terminology  for  the  domain  of  adherence  [30],  and  the  proposal  to  include  terms  of
adherence in the amendment to ISO 13940 (System of concepts to support continuity of
care) currently in progress in ISO TC 215 [31].
However,  there  are  still  many  challenges  with  the  use  of  Big  Data  for  adherence
assessment.  Without  standard  metrics,  the  same data  may  lead  to  diverse  results,  as
clearly depicted by a study of Malo et al. which found different mean adherence values and
proportions of adherent  patients when using medication possession ratio (MPR) versus
proportion of days covered (PDC) [32].
To date, numerous studies of adherence have been undertaken, using diverse approaches
to data analysis, which have led to mixed results. Most often, pharmacy records are used to
measure adherence in terms of implementation and discontinuation [33]. EHR data have
also been used for effective prediction of medication adherence trajectories [34], which has
evoked  certain  discussion  [35].  Menditto  et  al.  managed  to  integrate  and  analyse  six
databases from 3 countries, which allowed for a fair comparison of medication adherence
across  the  various  countries  [36].  Another  study  managed  to  assess  and  compare
adherence  to  chronic  medication  across  three  European  cohorts  of  older  people  by
developing a common protocol and using structured documents for sharing and applying
methodologies [37]. 
Some attempts to introduce standards to adherence assessment in Big Data have also
been  made  by  ISPOR  (International  Society  for  Pharmacoeconomics  and  Outcomes
Research). ISPOR Medication Adherence and Persistence Special Interest Group produced
recommendations  for  assessment  of  initial  medication  adherence  [38]  and  proposed  a
checklist for medication adherence studies using retrospective databases [39]. Arnet et al.
[40]. as well as Raebel et al. [41] proposed standard definitions and their operationalization
to quantify adherence to medication from electronic databases. Lehnman  et al. [42] and
Williams et al. [43] suggested some basic guidance regarding use of pharmacy refill data to
assess adherence. At the same time, a systematic review of publications on adherence in
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older  Americans,  identified  as  many  as  20  differently  named  measures  of  adherence
derived  from  pharmacy  claims  data  [44].  Even  more  interestingly,  some  adherence
measures derived from Big Data are already in use for incentivizing healthcare providers to
consider long-term health outcomes. In the US, Centers for Medicare & Medicaid Services
adopted several quality measures using the threshold of PDC≥0.8 for the drug(s) under
measurement, for a period of 12 consecutive months [45]. In fact, there is evidence that this
improves adherence [46].
Moreover, another important question that needs to be addressed in future standardized
measures of adherence in Big Data is: what is the subject of adherence assessment: a
drug, a condition,  or a  patient? In  other  words,  how to measure adherence to  multiple
medications prescribed for the same condition, and/or to various conditions in patients with
multimorbidity  [47].  Indicators  designed  and  widely  used  to  evaluate  single-medication
adherence  are  not  necessarily  valid  for  assessment  of  adherence  to  polypharmacy
regimens [48]. For example, a study assessing adherence in individuals belonging to the
Epichron  cohort  returned  highly  diverse  results  for  various  drug  classes:  72.4%  for
antidiabetics versus only 44.3% for lipid-lowering drugs [49]. A recent systematic review
found serious inconsistency in the measures used to estimate adherence and persistence
to multiple cardiometabolic medications [50],  while another review concluded that ‘there
appears to be no standardized method to measure multiple medication adherence’ [51]. For
sure,  further  research is  needed in  this  respect  and is  particularly  important  given  the
ageing population.
In summary the major disadvantage of the current lack of widely accepted standards for
adherence assessment is the difficulty in comparing and interpreting scientific study results.
Uniform adherence measurement and a common ontology urgently need to be developed,
in order to support research and to enable real life implementation of study findings [40, 52,
53].  This  is  also  necessary  for  cross-study  comparisons  and  fair  benchmarking  of
adherence-targeting interventions. 
Need for standard Big Data-related adherence metrics for clinical practice, public health and
health policy
Big Data and the development of a standardized measure of adherence may enable more
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reliable and valid investigations into the association between non-adherence and health
outcomes.  To  date  there  is  no  consensual  standard  for  what  constitutes  adequate
adherence. In practice, 80% is often used as a cut-off to classify “good adherence” but
scientific evidence for this threshold is unclear. In fact, a systematic review investigated
medication adherence thresholds in relation to clinical outcomes and found the included
studies  to  be  highly  heterogeneous  and  could  not  confirm or  reject  the  validity  of  the
historical 80% cut off threshold for adherence [54]. Moreover, many treatments are also
preventative and it may take a very long time to determine any therapeutic benefit at all
from such treatments. 
Various interventions have been designed in order to prevent and manage non-adherence
in real life settings. Unfortunately, despite objective need, these interventions are generally
underused. Lack of standardised comparable measures of adherence is one of the major
barriers towards the objective selection of the most effective and cost-effective interventions
[2], and the scaling-up of best practice. Only with reliable and valid measures, can non-
adherence be tracked along a timeline, allowing the assessment of the long-term effects of
particular interventions, and the benchmarking of their effectiveness. Standard measures
and guidelines to assess adherence could also facilitate the introduction as well  as the
assessment of the effectiveness of incentives to promote adherence at the patient, provider
and payers level and the ability to target individual risk factors at the various health care
provider levels [55].
Standardized adherence measures employed to Big Data sets may also provide an insight
into the reasons why patients do not adhere to their prescribed medication regimens. This
is of utmost importance as a review of systematic reviews identified 771 individual factor
items as possible determinants of non-adherence, concluding that “a lack of standardized
adherence  definitions  and  use  of  poor  measurement  methods  resulted  in  many
inconsistencies in the findings and many of the identified factors had an inconsistent effect
on adherence” [56]. 
Thus, Big Data sets are useful  to assess adherence in different profiles of  drug users,
analyse the factors related to adherence, explore causes of discontinuation and to compare
results across different populations. With this information, drug users at the highest risk of
non-adherence  can  be  identified  and  tailored  interventions  can  be  designed  and
implemented. It is of paramount importance to consider that most of current interventions to
address  adherence  are  using,  or  are  based  on  IT  (Information  Technology)  solutions.
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These,  however,  are not  currently  based on standardized measures of  adherence [55].
Another  potential  technology  approach  for  prediction  and  assessment  of  adherence  is
Artificial Intelligence (AI). With AI onboard, Big Data may be analysed both retrospectively,
as  well  as  in  real  time,  allowing  for  more  personalized  healthcare.  However,  a  major
hindrance to the adoption of AI is, yet again, the lack of sound operational measures of
adherence to properly train the algorithms. 
Along  with  individual  health,  public  health  is  sure  to  benefit  from  the  introduction  of
standardised measures of adherence. Such measures will enable comparison of adherence
rates within and across different countries, populations and disease groups, allowing for fair
benchmarking of interventions, better planning and practical implementation. In fact, more
and more often, medication adherence is accepted as a measure of the quality of care
provided by physicians as well  as the quality and effectiveness of the entire healthcare
system [55, 57]. Also in this area, lack of standardised measures causes the problem of
non-adherence to be often overlooked in national agendas. In fact, only a few countries
systematically  monitor  adherence.  Therefore,  the  recent  OECD  report  calls  for
standardization in order to allow for international benchmarking [55].
Recent  outbreak  of  COVID-19  pandemic  proved  the  extraordinary  role  that
infoepidemiology  (i.e.  information  epidemiology)  can  play  in  the  management  of  major
public  health  problems  [58].  Let  this  lesson  be  the  inspiration  for  wider  adoption  of
digitization in healthcare, in general, and faster utilization of the potential of Big Data for the
management of adherence, in particular.
Conclusions
Ongoing digitization of the healthcare sector, and availability of Big Data repositories create
unprecedented opportunity to study patient adherence at a mass scale, both retrospectively
and in real time. Obvious benefits that could be derived for science, as well as for individual
and public health, are hindered by the current lack of standards of adherence-related data
analysis. What sort of standards need to be agreed to change this scenario? Firstly, there
needs to be a standard format for the data collected in Big Data databases – such as
EHRs, as well as prescribing and dispensing registers – to allow for smooth and effective
assessment of adherence parameters. Secondly, sound metrics need to be developed to
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process this  raw data.  Thirdly,  standards of  presentation of  adherence measures being
assessed within Big Data need to be agreed.
Bearing in mind the troublesome history of  healthcare sector digitization,  this plan may
appear to be ambitious. However, the authors of this publication are motivated to face the
challenge  and  develop  these  highly  needed  global  standards,  discuss  them  with  the
scientific world and finally, agree a common consensus. Therefore, everybody interested is
invited  to  join  our  efforts  within  the  new  initiative  that  we  want  to  call  DIGI.PASs  -
introducing Patient Adherence Standard measures to be used with Big Data collections
available in the DIGItal repositories.
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